Covid-19: FDA allows emergency use of antibody drug Regeneron
|bbc.com 22 Nov 2020 at 06:18|
US officials have granted emergency authorisation for an experimental antibody treatment given to President Trump after his Covid-19 diagnosis.
The drug, developed by Regeneron, will be allowed for use in people who have tested positive for the virus and are at risk of severe illness.
Studies suggest the therapy is effective when administered early after diagnosis, the company says.
It comes as Covid-19 cases in the country continue to rise.
Emergency authorisation by the Food and Drug Administration (FDA) allows use of a treatment while studies are carried out to determine safety and effectiveness.
A similar drug made by Eli Lilly, another US pharmaceutical firm, was given emergency approval earlier this month.
The Regeneron treatment is a combination of two monoclonal antibodies - potent, laboratory-made antibodies - which mimic our own immune response. They physically stick to the coronavirus so they cannot get inside the body s cells.
Regeneron said it expected to have enough doses for about 80,000 patients by the end of this month and 300,000 in total by the end of January. The treatment will be provided for free but patients may have to pay for having it administered.
The FDA said the treatment was not authorised for Covid patients who are in hospital or require oxygen.
image captionThe emergency authorisation comes as the US sees a sharp rise in Covid-19 cases
after testing positive for Covid-19 in October. The president later credited the experimental therapy for aiding his recovery - though it remains impossible to know whether it did.
President Trump was one of only a handful of people outside clinical trials to be given the drug, under what is known as "compassionate use".
Meanwhile, US Housing Secretary Ben Carson said he believed he was "out of the woods" after being "extremely sick" following his positive Covid diagnosis earlier this month.